The government is expected to extend the deadline for small drug companies to comply with the revised Schedule M standards ...
The beverage giant is ready to manage, mitigate and adjust to the “dynamic macro environment,” including potential tariffs ...
Developing effective treatments and understanding how the mechanism of the immune system have always been challenging for ...
Navigating regulatory hurdles in the U.S. and Europe, plus fierce competition from rival Apellis, Astellas’ geographic ...
Q1 2025 Management View CEO Christopher Missling highlighted key updates on the Alzheimer's treatment, blarcamesine. He emphasized the potential of the drug to offer "a scalable treatment alternative ...
COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Wednesday it plan to file its experimental next-generation obesity drug CagriSema for regulatory approval during the ...
Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...
The Budget Estimates (BE) for the Centrally Sponsored Scheme of Strengthening of States Drug Regulatory System (SSDRS) for the fiscal year 2025-26 is Rs. 50 crore, around 33 per cent less than the ...
As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results